EHA 2017 Congress Highlights in Multiple Myeloma

Please Log In or Register to continue.

Release Date: July 26, 2017
Expiration Date: July 26, 2018

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will learn about key highlights of the most impactful and up-to-date clinical trial data in multiple myeloma (MM), presented at the 2017 European Hematology Association (EHA) 22nd Congress.

  • Efficacy of Ixazomib Maintenance in Myeloma Patients
  • Efficacy of Venetoclax in Patients with RRMM
  • Evaluating Long-term Prognosis in MM Patients: Lenalidomide, Maintenance and MRD
  • The Connect® MM Registry Trial: Results Across the Disease Spectrum
  • Denosumab for Bone Disease in NDMM
  • IRd in Newly Diagnosed MM Patients
  • First-in-Human Multicenter Trial of CAR-T Cells in RRMM Patients
  • Efficacy of Daratumumab in RRMM: Two- vs Three-Drug Combinations and Cytogenetic Risk

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with multiple myeloma (MM)
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MM
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in MM

Agenda

  • Efficacy of Ixazomib Maintenance in Myeloma Patients (S408) – Shaji Kumar, MD
  • Efficacy of Venetoclax in Patients with RRMM (P675) – Shaji Kumar, MD
  • Evaluating Long-term Prognosis in MM Patients: Lenalidomide, Maintenance and MRD – Philip L. McCarthy, MD
    • Analysis of Crossover Trial Data for Lenalidomide vs Placebo in MM Patients (P332)
    • The Impact of Lenalidomide Maintenance Following Diverse Induction Regimens (S781)
    • MRD Measurement as an Indicator of Long-term Prognosis in MM Patients (S102)
  • The Connect® MM Registry Trial: Results Across the Disease Spectrum – Philip L. McCarthy, MD
    • SCT vs Maintenance in Post-induction MM Patients: Registry Study Results (E1239)
    • Impact of Lenalidomide Maintenance on Quality of Life in MM Patients (E1277)
    • 11;14 Translocation in African American MM Patients (P349)
  • Denosumab for Bone Disease in NDMM (S782) – Noopur Raje, MD
  • IRd in Newly Diagnosed MM Patients (S780) – Noopur Raje, MD
  • First-in-Human Multicenter Trial of CAR-T Cells in RRMM Patients (S142) – Noopur Raje, MD
  • Efficacy of Daratumumab in RRMM: Two- vs Three-Drug Combinations and Cytogenetic Risk – Jesús San Miguel, MD
    • Efficacy of Daratumumab in RRMM: Effect of Cytogenetic Risk (S101)
    • Efficacy of Daratumumab in RRMM: Two- vs Three-Drug Combinations (P334)

Instructions for Participation and Credit

This activity is eligible for credit through July 26, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Shaji K. Kumar, MD
Professor of Medicine
Mayo Clinic College of Medicine
Consultant, Division of Hematology
Medical Director, Cancer Clinical Research Office
Mayo Clinic
Rochester, Minnesota

Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. He is currently the Medical Director for the Cancer Center Clinical Research Office which oversees the development, activation, conduct, and monitoring of interventional trials across the three site Mayo Clinic Cancer Center.

Certified by the American Board of Internal Medicine (ABIM) in internal medicine, medical oncology, and an ABIM diplomate in hematology, Dr. Kumar holds membership in several professional organizations including the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Blood and Marrow Transplantation, the Association of Physicians of India, and the European Hematology Association. He has published numerous articles, abstracts, editorials, and letters in the peer-reviewed literature, including Blood, Journal of Clinical Oncology, Leukemia, American Journal of Hematology, British Journal of Haematology, and Bone Marrow Transplantation. He is also a member of the editorial board for several journals including American Journal of Hematology, European Journal of Clinical and Medical Oncology, and Leukemia.

Dr. Kumar’s research focuses on the development of novel drugs for the treatment of myeloma, and he has presented nationally and internationally. He is the principal investigator of several phase 1 and phase 2 clinical trials exploring new drugs and combinations for newly diagnosed and relapsed myeloma. His laboratory is focused on understanding the role of bone marrow microenvironment in the development and progression of myeloma.

Philip L. McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York

Dr. Philip McCarthy received his medical degree from Tufts University School of Medicine, Boston, Massachusetts. He completed an internship and residency at Yale-New Haven Hospital, and hematology and medical oncology fellowship training at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. McCarthy is Professor of Oncology and Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, Buffalo. He is also Professor of Internal Medicine at the State University of New York at Buffalo.

Dr. McCarthy is a diplomate, American Board of Internal Medicine, with subspecialty certification in medical oncology and hematology, and holds membership in the American Society of Hematology (ASH), American Society for Blood and Marrow Transplantation (ASBMT), American Society of Clinical Oncology (ASCO), American Association of Blood Banking (AABB), and the American Association for Cancer Research (AACR). He is associate chair of the Myeloma Committee of the Alliance for Clinical Trials in Oncology (ACTION) and a member of the Transplant Committee. He is an associate editor of the Biology of Blood and Marrow Transplantation journal, as well as an ad hoc reviewer for several journals including Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, Haematologica, Leukemia and Lymphoma, and JNCCN. Dr. McCarthy has published more than 200 peer-reviewed manuscripts and reviews. His major research interests include blood and marrow transplantation, graft-versus-host disease/graft-versus-tumor effect, cancer immunotherapy, and multiple myeloma.

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.

Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.

Jesús San Miguel, MD, PhD
Professor of Medicine-Hematology
Director of Clinical and Translational Medicine
University of Navarra
Navarra, Spain

Dr. Jesús San Miguel is Professor of Medicine-Hematology and Director of Clinical and Translational Medicine at the University of Navarra in Spain. He served as Director of the Hematology Department of the University Hospital of Salamanca in Spain for more than 22 years (1991-2013). Dr. San Miguel is currently President of the International Myeloma Society and a member of the Advisory Board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation. In addition, he has served as board councillor for the European Association, chairman of the Scientific Committee for the IXth Congress (2004), president of the 15th European Hematology Association (EHA) Congress, and was associate editor for Blood and Haematologica.

Dr. San Miguel has published more than 780 original papers in international journals. He has made important contributions to myeloma cell biology in immunophenotyping, risk of progression from monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (MM) into active MM, and minimal residual disease, as well as in therapeutics, including studies for new antimyeloma drugs at the preclinical and clinical levels, which include proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and histone deacetylases (HDACs). Dr. San Miguel has received numerous awards, including the Waldenström Award, EBMT Lecture, Celgene Career Achievement Award, Kyle Lifetime Achievement Award, Jose Carreras EHA Award, Ham-Wasserman Lecture Award, Rey Jaime I Award in Clinical Medicine, and the Spanish Prizes in both oncology and translational research.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-161-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-161-061

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Shaji Kumar has received honoraria as a consultant from AbbVie Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Merck & Co., Inc., Skyline Diagnostics B.V., and Takeda Oncology. He has received grant support related to research activities from AbbVie, Celgene Corporation, Janssen, F. Hoffmann-La Roche Ltd, Merck, Sanofi, and Takeda Oncology.

Dr. Philip McCarthy has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Karyopharm Therapeutics, and Sanofi. He has received grant support related to research activities from Celgene.

Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology. She has received grant support related to research activities from AstraZeneca.

Dr. Jesús San Miguel has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Novartis AG, Sanofi, and Takeda Oncology.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.